Merck Drops Zocor Combo, But Keeps Going With Tredaptive
This article was originally published in The Pink Sheet Daily
Executive Summary
A brief mention in an SEC filing revealed that Merck has ceased the development of a combination cholesterol pill; the once hot ‘0524 program had languished in late-stages for several years.
You may also be interested in...
Getting Back Into CV?
Merck’s recent sale of its consume health business to Bayer involved a side bet on a new class of antihypertensive, which could mark a return to cardiovascular for Merck.
Another Low Blow For Raising HDL; Merck’s Tredaptive Fails Phase III Trial
With Tredaptive’s failure to meet the primary endpoint in the HPS2-THRIVE study, Merck announces it does not plan to seek regulatory approval of the niacin/laropiprant combination pill in the U.S.
Merck’s Frazier Optimistic About Pipeline Future
Merck’s Ken Frazier spoke about his faith in anaceptrapib, despite the recent failure of Tredaptive, at the recent Goldman Sachs Conference. He also addressed Merck’s pipeline and consolidation in the industry.